Insulin Regular — Competitive Intelligence Brief

Insulin Regular (Insulin Regular) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Insulin (short-acting). Area: Diabetes.

marketed Insulin (short-acting) Insulin receptor Diabetes Small molecule

Target snapshot

Insulin Regular (Insulin Regular) — The University of Texas Medical Branch, Galveston. Insulin Regular binds to insulin receptors on cells to promote glucose uptake and utilization, lowering blood glucose levels.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Insulin Regular TARGET	Insulin Regular	The University of Texas Medical Branch, Galveston	marketed	Insulin (short-acting)	Insulin receptor
Tresiba	INSULIN DEGLUDEC	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2015-01-01
Levemir	INSULIN DETEMIR	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2005-01-01
Apidra	INSULIN GLULISINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2004-01-01
Lantus	INSULIN GLARGINE	Sanofi	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Novolog	INSULIN ASPART	Novo Nordisk	marketed	Insulin Analog [EPC]	Insulin receptor	2000-01-01
Humalog	INSULIN LISPRO	Eli Lilly	marketed	Insulin Analog [EPC]	Insulin receptor	1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Insulin (short-acting) class)

1. Fundación Pública Andaluza Progreso y Salud · 1 drug in this class
2. HaEmek Medical Center, Israel · 1 drug in this class
3. The University of Texas Medical Branch, Galveston · 1 drug in this class